Northwind Pharmaceuticals, a rapidly growing national provider of prescription medications, chronic care programs, and pharmacy benefits, adds former Marathon Health CEO Jerry Ford to its strategic advisory board.
Read Press ReleaseThe agreement will drive the discovery of more effective treatments for cardiovascular disease and development of safer drugs with the preclinical implementation of advanced human heart models
Read Press ReleaseIn the Digital Health and Startups category at the 2023 Consumer Electronics Show (CES), Eyenovia showcased its Microdose Array Print (MAP™) Technology, the first significant advancement in ocular drug delivery methods in over a century.
Read Press ReleaseThe appointment further strengthens the company's scientific resources, including in neuronal function and synaptic transmission, which are central to Neurocentria's approach for developing novel therapies for neurodegenerative and neuropsychiatric disorders.
Read Press Release•• Complete epithelial recovery was achieved by 67% of subjects receiving NEXAGON, as opposed to 27% receiving Vehicle alone
•• NEXAGON was well-tolerated demonstrating a safety profile similar to vehicle
•• Amber plans to initiate the NEXPEDE-1 Phase 2/3 clinical trial in subjects with PCED of various etiologies in Q1 2023 ••
The Microdose Array Print (MAP) Technology has shown potential in clinical trials, providing the possibility of more accurate ocular drug delivery than traditional eye droppers
Read Press ReleaseGb Sciences' innovative approach harnesses the power of plant-based treatments as simplified mixtures that target dangerous hyperinflammatory responses to viral infections.
Read Press ReleaseAs mental health disorders increasingly impact global populations, Gb Sciences is developing psychotropic but non-psychedelic treatments for anxiety and depression that compete with the emerging billion-dollar psychedelic companies.
Read Press ReleasePresentation to include clinical data from a phase 2 study of Gruticibart (AB023), a factor XI-targeted antibody being developed for the treatment and prevention of thrombosis and inflammation
Read Press ReleaseP23 Labs, a leading molecular laboratory, is kicking off its 23 Days of Giving series of charitable events running from Dec. 1 to Dec. 23, 2022. Three of these days will be dedicated to gifts to the company's team members and 20 days are for charitable donations to causes from P23 and its partner, Laddia Whittier, who made a generous contribution to make this initiative possible.
Read Press ReleaseNext-generation proteomics technology made available to the biotech and pharmaceutical industry through the acquisition of Methuselah Health by leading R&D services provider, RxCelerate
Read Press ReleaseState-of-the-art system of neural networks and machine learning models that transforms non-numeric healthcare provider voice responses at scale into measurable insights.
Read Press ReleaseComing in overall at 125th, Apprentice is recognized for its 1,159% revenue growth as it continues to scale its Tempo Manufacturing Cloud platform for Life Sciences.
Read Press ReleaseExpert life science compliance consulting firm TRESTLE Compliance partners with qordata to leverage TRESTLE's compliance expertise and qordata's compliance management tools to provide life science innovators comprehensive compliance solutions that mitigate risks and maximize effectiveness.
Read Press ReleaseAs published in the journal Food and Chemical Toxicology, the biopharmaceutical drug development firm's sponsored research used co-cultured human, primary immune cells as a model to evaluate the ability of selected Cannabis constituents to decrease inflammation.
Read Press ReleaseAt the Annual Summit, Dr. Andrea Small-Howard is presenting a Keynote Address that includes data from case studies demonstrating the utility of Gb Sciences' proprietary PhAROS drug discovery platform.
Read Press ReleaseClinical Research Division to Offer Full-Service Support, Removing Barriers to Kidney Care Innovation by Providing Access to Large Patient Populations, Trial-Ready Sites, Principal Investigators
Read Press ReleaseGb Sciences' anxiety formulations were previously identified using the company's AI-driven PhAROS™ platform, and they have now been evaluated using preclinical zebrafish models of stress at the National Research Council of Canada.
Read Press ReleaseThe Optejet® ophthalmic drug device is designed to precisely administer medication to the eye, potentially treating patients' conditions through gentler, more efficient dosing.
Read Press ReleaseDr. Andrea Small-Howard discusses the company's novel process for developing disease-specific, cannabinoid-based therapeutics.
Read Press ReleaseAmbit to showcase its prevalence projection approach, co-developed with Praxis, for rare developmental and epileptic encephalopathies (DEEs) as a Platform Presentation at this year's annual Child Neurology Society meeting
Read Press ReleaseAs published in Frontiers in Pharmacology, the biopharmaceutical drug development firm's sponsored research has identified and validated cannabinoid ratio-controlled, Minimum Essential Mixtures (MEM) for the treatment of Parkinson's disease symptoms
Read Press ReleaseAcquisition allows Pace® to provide full-service regulatory strategy and consulting services to advance FDA submissions across a wide range of therapeutic classes.
Read Press Release